Detalhe da pesquisa
1.
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
Lancet Oncol
; 22(6): 813-823, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34000245
2.
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives.
Oncologist
; 26(10): 865-878, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34105205
3.
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Acta Neuropathol
; 141(6): 945-957, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740099
4.
Predictive markers of immune response in glioblastoma: hopes and facts.
Future Oncol
; 16(15): 1053-1063, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32270715
5.
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 20(1): 110-119, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30522967
6.
Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas.
Future Oncol
; 15(22): 2595-2601, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31339049
7.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Lancet
; 390(10103): 1645-1653, 2017 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28801186
8.
How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments.
Expert Rev Clin Pharmacol
; 16(1): 17-26, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576307
9.
Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022.
Expert Opin Drug Discov
; 18(3): 269-286, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36718723
10.
Cytologically confirmed splenic metastases in breast cancer.
Future Oncol
; 8(11): 1495-500, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23148622
11.
Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance.
Front Oncol
; 12: 852950, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35311140
12.
Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?
Cancers (Basel)
; 14(2)2022 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35053495
13.
Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?
Drugs
; 82(5): 491-510, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35397073
14.
Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
Immunotherapy
; 14(10): 799-813, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35670093
15.
Tumor-Associated Microenvironment of Adult Gliomas: A Review.
Front Oncol
; 12: 891543, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35875065
16.
Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology.
Biomedicines
; 10(12)2022 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36551961
17.
Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis.
Adv Ther
; 39(1): 165-177, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34853984
18.
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study.
Tumori
; 108(4): 331-337, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34002658
19.
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
Expert Rev Anticancer Ther
; 21(12): 1333-1353, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34734551
20.
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Mol Diagn Ther
; 25(4): 457-473, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34095989